| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |